Full-Time
Commercial services for pharmaceutical lifecycle management
$170k - $210k/yr
Dallas, TX, USA
Remote
Bachelor's
See people who can refer or advise you
EVERSANA provides integrated commercial services to pharmaceutical and biotech companies across the product lifecycle. It helps with drug pricing, market access, reimbursement, patient adherence, and product delivery through a service-based model. Its solutions are delivered via a global network of 30+ locations, including consulting, market access strategies, patient services, and field deployment. The goal is to help clients bring products to market, optimize pricing and access, improve adherence, and ensure efficient delivery to improve patient outcomes and commercial performance.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Milwaukee, Wisconsin
Founded
2018
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Holidays
401(k) Retirement Plan
401(k) Company Match
Wellness Program
Mental Health Support
Conference Attendance Budget
EVERSANA, a global provider of commercial services to the life sciences industry, has appointed Jen Norton as President, Market Access & Value. Norton will lead a new dedicated market access business unit integrating EVERSANA's services across global pricing, revenue management, value and evidence, and consulting. Norton brings over 20 years of market access leadership experience. She joins from Takeda, where she served as Senior Vice President and Head of U.S. Patient and Market Access, and previously held senior positions at Amgen and Biogen. The new unit reinforces EVERSANA's commitment to helping clients navigate the complex pricing and access landscape. CEO Mark Thierer said successfully navigating market access is amongst the most critical challenges clients face today. EVERSANA serves over 650 organisations in the life sciences industry.
EVERSANA has appointed Mike Guarino as chief executive officer of EVERSANA INTOUCH, its global health agency. Guarino will lead strategy and operations across the agency's capabilities, focusing on integrating commercialisation opportunities through data and AI to deliver marketing solutions for life sciences clients. Guarino brings extensive agency experience, most recently serving as chief commercial officer at IPG Health. He spent over two decades in senior roles at FCB Health and co-founded Area 23. Senior leaders including Ann Cave, Susan Perlbachs, John Kenny and Dan Gandor will report to Guarino. Founder Faruk Capan will shift focus to expanding the company's AI Agency platform, launched in collaboration with Google in August 2025. EVERSANA provides commercial services to the life sciences industry, serving over 650 organisations globally.
Candel Therapeutics announces commercial agreement with EVERSANA to support U.S. launch of prostate cancer therapy. Candel Therapeutics, a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to help patients with cancer, today announced that it entered into a product commercialization agreement with EVERSANA, a provider of global commercialization services to the life sciences industry, to support the potential U.S. commercial launch of aglatimagene besadenovec (aglatimagene or CAN-2409) for the treatment of intermediate- to high-risk, localized prostate cancer. Under the terms of the agreement, EVERSANA will provide Candel with a broad suite of integrated commercialization services including data and analytics, medical affairs, market access, and field operations. EVERSANA joins IDEA Pharma, a division of SAI MedPartners (IDEA), which has been providing path-to-market strategies and strategic positioning for aglatimagene. Candel has worked in close collaboration with both EVERSANA and IDEA on key pre-commercial workstreams as previously announced during Candel's virtual Research and Development Day in December 2025. This collaboration reflects Candel's deliberate approach to building a world class commercial organization with global reach, designed from the ground up and leveraging a team of highly experienced professionals poised to support the potential commercial launch of aglatimagene for the treatment of intermediate- to high-risk, localized prostate cancer, subject to regulatory approval. This operating model gives Candel access to leading commercial capabilities while maintaining financial flexibility, capital efficiency, and scientific focus that has driven Candel's progress to date. "From the beginning, we designed Candel's commercial strategy around a partner-led model that allows us to stay focused on advancing the science and navigating the regulatory pathway, while having access to world-class commercial capabilities on demand," said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. "With the addition of EVERSANA, that model is fully in place, and with the progress we've already made across our pre-commercialization workstreams, we have confidence in our readiness for the potential commercial launch of aglatimagene for the treatment of intermediate- to high-risk, localized prostate cancer. We look forward to working with EVERSANA and IDEA Pharma in providing a novel and potentially invaluable therapeutic for localized prostate cancer patients." "We are proud to support Candel as it advances what could be a new and potentially transformative treatment option for patients with localized prostate cancer," said Gregory Skalicky, President of EVERSANA. "Candel's unique approach to commercialization, building a dedicated and flexible platform with specialized partners, rather than a fixed pharmaceutical infrastructure, is exactly the type of model EVERSANA was designed to support. We have already integrated our resources alongside the Candel team, with key commercial workstreams actively underway, and we look forward to helping ensure that aglatimagene reaches patients efficiently and effectively upon potential approval."
Xcovery Holdings has partnered with EVERSANA to support the US commercial launch of Ensacove (ensartinib), a novel therapy for adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK inhibitor. Under the agreement, EVERSANA will provide comprehensive end-to-end commercialisation services, including market access and commercial and medical teams. Ensacove is a next-generation ALK inhibitor jointly developed by Xcovery and Betta Pharmaceuticals and is now available in the United States. The partnership aims to expand patient access across the US by leveraging EVERSANA's commercialisation capabilities and experience in the life sciences industry. EVERSANA serves over 650 organisations globally, including pharmaceutical startups and established companies.
EVERSANA names new chief legal officer. EVERSANA has named Monica Avram as Executive Vice President and Chief Legal Officer, a strategic addition as the company scales operations and reinvents commercialization services. As Chief Legal Officer and a member of the Executive Leadership Team, Monica leads the company's global Legal and Compliance function. Her strategic leadership integrates governance, risk, and operational execution to enable innovation, strengthen enterprise performance, and drive long-term value. With more than two decades of experience at top law firms and across global Fortune 100 companies - including UnitedHealth Group and Sanofi - Avram brings deep expertise at the intersection of healthcare, law, and emerging technologies. She has built high-performing, financially disciplined legal teams, advised executive leadership and boards on enterprise strategy, and guided organizations through complex regulatory and operational environments. "As we continue to scale, it's paramount that we have top talent who can understand the complexity of our industry and bring proven track records of success," said Mark Thierer, CEO, EVERSANA. "Throughout her career, Monica has demonstrated exceptional leadership in building best-in-class legal organizations, and we're thrilled to welcome her to EVERSANA." She brings seasoned board and advisory experience across public companies and nonprofit organizations, with deep expertise in governance, oversight, and strategic leadership. Avram holds a BA in Biology from the University of Missouri - Kansas City and a Juris Doctor from Suffolk University Law School.